Response to: The BRAIN TRIAL: a randomized, placebo controlled trial of a Bradykinin B2 receptor antagonist (Anatibant) in patients with traumatic brain injury - authors' reply

A response to the letter regarding The BRAIN TRIAL: a randomized, placebo controlled trial of a Bradykinin B2 receptor antagonist (Anatibant) in patients with traumatic brain injury, by Mr Vincent Simmon President and CEO of Xytis Inc.

Detalles Bibliográficos
Autores principales: Roberts, Ian, Shakur, Haleema
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2009
Materias:
Letter
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2797008/
http://dx.doi.org/10.1186/1745-6215-10-111
_version_ 1782175580808019968
author Roberts, Ian
Shakur, Haleema
author_facet Roberts, Ian
Shakur, Haleema
author_sort Roberts, Ian
collection PubMed
description A response to the letter regarding The BRAIN TRIAL: a randomized, placebo controlled trial of a Bradykinin B2 receptor antagonist (Anatibant) in patients with traumatic brain injury, by Mr Vincent Simmon President and CEO of Xytis Inc.
format Text
id pubmed-2797008
institution National Center for Biotechnology Information
language English
publishDate 2009
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-27970082009-12-23 Response to: The BRAIN TRIAL: a randomized, placebo controlled trial of a Bradykinin B2 receptor antagonist (Anatibant) in patients with traumatic brain injury - authors' reply Roberts, Ian Shakur, Haleema Trials Letter A response to the letter regarding The BRAIN TRIAL: a randomized, placebo controlled trial of a Bradykinin B2 receptor antagonist (Anatibant) in patients with traumatic brain injury, by Mr Vincent Simmon President and CEO of Xytis Inc. BioMed Central 2009-12-03 /pmc/articles/PMC2797008/ http://dx.doi.org/10.1186/1745-6215-10-111 Text en Copyright ©2009 Roberts and Shakur; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Letter
Roberts, Ian
Shakur, Haleema
Response to: The BRAIN TRIAL: a randomized, placebo controlled trial of a Bradykinin B2 receptor antagonist (Anatibant) in patients with traumatic brain injury - authors' reply
title Response to: The BRAIN TRIAL: a randomized, placebo controlled trial of a Bradykinin B2 receptor antagonist (Anatibant) in patients with traumatic brain injury - authors' reply
title_full Response to: The BRAIN TRIAL: a randomized, placebo controlled trial of a Bradykinin B2 receptor antagonist (Anatibant) in patients with traumatic brain injury - authors' reply
title_fullStr Response to: The BRAIN TRIAL: a randomized, placebo controlled trial of a Bradykinin B2 receptor antagonist (Anatibant) in patients with traumatic brain injury - authors' reply
title_full_unstemmed Response to: The BRAIN TRIAL: a randomized, placebo controlled trial of a Bradykinin B2 receptor antagonist (Anatibant) in patients with traumatic brain injury - authors' reply
title_short Response to: The BRAIN TRIAL: a randomized, placebo controlled trial of a Bradykinin B2 receptor antagonist (Anatibant) in patients with traumatic brain injury - authors' reply
title_sort response to: the brain trial: a randomized, placebo controlled trial of a bradykinin b2 receptor antagonist (anatibant) in patients with traumatic brain injury - authors' reply
topic Letter
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2797008/
http://dx.doi.org/10.1186/1745-6215-10-111
work_keys_str_mv AT robertsian responsetothebraintrialarandomizedplacebocontrolledtrialofabradykininb2receptorantagonistanatibantinpatientswithtraumaticbraininjuryauthorsreply
AT shakurhaleema responsetothebraintrialarandomizedplacebocontrolledtrialofabradykininb2receptorantagonistanatibantinpatientswithtraumaticbraininjuryauthorsreply

Ejemplares similares